AR099963A2 - Formulación farmaceutica en aerosol para inhaladores de dosis medida presurizados que comprenden un agente secuestrante, inhalador y método para llenar - Google Patents
Formulación farmaceutica en aerosol para inhaladores de dosis medida presurizados que comprenden un agente secuestrante, inhalador y método para llenarInfo
- Publication number
- AR099963A2 AR099963A2 ARP150101030A ARP150101030A AR099963A2 AR 099963 A2 AR099963 A2 AR 099963A2 AR P150101030 A ARP150101030 A AR P150101030A AR P150101030 A ARP150101030 A AR P150101030A AR 099963 A2 AR099963 A2 AR 099963A2
- Authority
- AR
- Argentina
- Prior art keywords
- hfa
- phosphoric acid
- inhaler
- aerosol
- budesonide
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000012163 sequencing technique Methods 0.000 title 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 6
- 238000009472 formulation Methods 0.000 abstract 4
- 150000005828 hydrofluoroalkanes Chemical class 0.000 abstract 4
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 abstract 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract 3
- 229960004436 budesonide Drugs 0.000 abstract 3
- 239000003380 propellant Substances 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 abstract 2
- 239000006184 cosolvent Substances 0.000 abstract 2
- 229960003957 dexamethasone Drugs 0.000 abstract 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 2
- 229960000676 flunisolide Drugs 0.000 abstract 2
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 abstract 2
- 239000003352 sequestering agent Substances 0.000 abstract 2
- 229960002117 triamcinolone acetonide Drugs 0.000 abstract 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 abstract 2
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 abstract 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 abstract 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000001298 alcohols Chemical class 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
Abstract
Reivindicación 1: Una formulación en aerosol para inhaladores de dosis medida presurizados, caracterizada porque consiste en 20-cetoesteroides seleccionados entre budesonida, flunisolida, triamcinolona acetonida, dexametasona y betametasona 17 valerato, un propelente HFA licuado, un cosolvente seleccionado entre alcoholes adecuados para uso farmacéutico, y un agente secuestrante seleccionado del grupo que consiste en ácido sulfúrico y fosfórico, donde la estabilidad química de los principios activos está mejorada. Reivindicación 2: La formulación de acuerdo con la reivindicación 1, caracterizada porque dicho propelente HFA licuado es por lo menos un elemento seleccionado entre el grupo que consiste en HFA 134a, HFA 227, y mezclas de los mismos. Reivindicación 3: La formulación de acuerdo con las reivindicaciones 1 ó 2, caracterizada porque dicho cosolvente es etanol. Reivindicación 13: La formulación de acuerdo con la reivindicación 1 caracterizada porque el 20-cetoesteroide es budesonida. Reivindicación 18: Un método para llenar un inhalador en aerosol de acuerdo con cualquiera de las reivindicaciones 14 a 17, caracterizado porque comprende: (a) agregar un 20-cetoesteroide seleccionado entre budesonida, flunisolida, triamcinolona acetonida, dexametasona y betametasona 17 valerato a uno o más cosolventes; (b) llenar dicho inhalador con dicha solución; (c) agregar una cantidad predeterminada de un agente secuestrante, seleccionado entre ácido fosfórico o ácido sulfúrico; (d) agregar a dicha solución un propelente que comprende un hidrofluoroalcano (HFA); y (e) embutir a presión la válvula y llenar con gas; donde dicho ácido fosfórico está presente en una cantidad equivalente a entre 0,0004 y 0,040% p/p, preferiblemente entre 0,0008 y 0,020% p/p, más preferiblemente entre 0,001 y 0,010% p/p de ácido fosfórico 15 M, calculado en base al peso total de la solución final, o donde dicho ácido sulfúrico está presente en una cantidad equivalente a entre 0,0005 y 0,02% p/p, preferiblemente entre 0,001 y 0,01% p/p, más preferiblemente entre 0,001 y 0,0072% p/p, más preferiblemente aún entre 0,002 y 0,0054% p/p de ácido sulfúrico 0,075 M, calculado en base al peso total de la composición.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05004233 | 2005-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099963A2 true AR099963A2 (es) | 2016-08-31 |
Family
ID=36490097
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20060100670A AR054230A1 (es) | 2005-02-25 | 2006-02-23 | Formulaciones farmaceuticas en aerosol para inhaladores de cartucho presurizados que comprenden un agente secuestrante |
| ARP150101030A AR099963A2 (es) | 2005-02-25 | 2015-04-06 | Formulación farmaceutica en aerosol para inhaladores de dosis medida presurizados que comprenden un agente secuestrante, inhalador y método para llenar |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20060100670A AR054230A1 (es) | 2005-02-25 | 2006-02-23 | Formulaciones farmaceuticas en aerosol para inhaladores de cartucho presurizados que comprenden un agente secuestrante |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8877164B2 (es) |
| EP (1) | EP1850831B1 (es) |
| JP (1) | JP5259193B2 (es) |
| KR (1) | KR101313959B1 (es) |
| CN (1) | CN101119706B (es) |
| AR (2) | AR054230A1 (es) |
| AU (1) | AU2006218177B2 (es) |
| BR (1) | BRPI0607990A2 (es) |
| CA (1) | CA2594127C (es) |
| EA (1) | EA013405B1 (es) |
| GE (1) | GEP20105040B (es) |
| IL (1) | IL184449A0 (es) |
| MA (1) | MA29333B1 (es) |
| MX (1) | MX2007010396A (es) |
| NO (1) | NO20074854L (es) |
| NZ (1) | NZ556376A (es) |
| PE (1) | PE20061011A1 (es) |
| SG (1) | SG159550A1 (es) |
| TN (1) | TNSN07289A1 (es) |
| UA (1) | UA92732C2 (es) |
| WO (1) | WO2006089656A2 (es) |
| ZA (1) | ZA200706870B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1746981B1 (en) * | 2004-05-13 | 2008-08-13 | CHIESI FARMACEUTICI S.p.A. | Medicinal aerosol formulation products with improved chemical stability |
| GB201200525D0 (en) * | 2011-12-19 | 2012-02-29 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable medicament |
| RU2519653C1 (ru) * | 2013-02-27 | 2014-06-20 | Шолекс Девелопмент Гмбх, | Аэрозольный препарат на основе ипратропия бромида для лечения заболеваний органов дыхания |
| US10034866B2 (en) * | 2014-06-19 | 2018-07-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalable medicament comprising tiotropium |
| US11826382B2 (en) | 2020-05-01 | 2023-11-28 | Tygrus, LLC | Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses |
| US11642372B2 (en) | 2020-05-01 | 2023-05-09 | Tygrus, LLC | Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses |
| US12042514B2 (en) | 2020-05-01 | 2024-07-23 | Tygrus, LLC | Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK280911B6 (sk) * | 1992-12-09 | 2000-09-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Farmaceutický prostriedok |
| ZA939195B (en) * | 1992-12-09 | 1995-06-08 | Boehringer Ingelheim Pharma | Stabilized medicinal aerosol solution formulations |
| CA2178473C (en) | 1993-12-20 | 2004-08-24 | Tsi-Zong Tzou | Flunisolide aerosol formulations |
| JPH11507359A (ja) * | 1995-06-07 | 1999-06-29 | ローヌ−プーラン ローラー ファーマシューティカルズ インコーポレイテッド | 安定化ステロイド組成物 |
| IL122752A (en) * | 1995-06-27 | 2001-07-24 | Boehringer Ingelheim Kg | Stable preparations for creating propellant-free sprays |
| DZ2947A1 (fr) * | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
| US6315985B1 (en) * | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
| IT1313553B1 (it) * | 1999-07-23 | 2002-09-09 | Chiesi Farma Spa | Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione. |
| WO2001087203A1 (en) * | 2000-05-17 | 2001-11-22 | Chrysalis Technologies Incorporated | Stabilized budesonide solution and method for making same |
| JP5392880B2 (ja) * | 2000-05-22 | 2014-01-22 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 加圧式定量吸入器のための安定な製薬学的溶液製剤 |
| EP3384931B1 (en) * | 2002-03-01 | 2019-07-24 | Chiesi Farmaceutici S.p.A. | Formoterol superfine formulation |
| US7417051B2 (en) | 2002-04-12 | 2008-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments comprising betamimetics and a novel anticholinergic |
| EP1497289B1 (de) | 2002-04-12 | 2005-08-24 | Boehringer Ingelheim Pharma GmbH & Co.KG | Arzneimittel enthaltend betamimetika und ein neues anticholinergikum |
| DE10230769A1 (de) | 2002-07-09 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren |
| US20040058950A1 (en) | 2002-07-09 | 2004-03-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
| DE10237739A1 (de) | 2002-08-17 | 2004-02-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika |
| WO2004033478A2 (en) * | 2002-10-08 | 2004-04-22 | Sepracor Inc. | Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory |
| EP1595531A1 (en) | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
-
2006
- 2006-02-13 CA CA2594127A patent/CA2594127C/en not_active Expired - Fee Related
- 2006-02-13 EA EA200701805A patent/EA013405B1/ru not_active IP Right Cessation
- 2006-02-13 NZ NZ556376A patent/NZ556376A/en not_active IP Right Cessation
- 2006-02-13 JP JP2007556521A patent/JP5259193B2/ja not_active Expired - Fee Related
- 2006-02-13 EP EP06706899.9A patent/EP1850831B1/en not_active Expired - Lifetime
- 2006-02-13 GE GEAP200610279A patent/GEP20105040B/en unknown
- 2006-02-13 UA UAA200707949A patent/UA92732C2/ru unknown
- 2006-02-13 KR KR1020077016131A patent/KR101313959B1/ko not_active Expired - Fee Related
- 2006-02-13 BR BRPI0607990-3A patent/BRPI0607990A2/pt not_active IP Right Cessation
- 2006-02-13 SG SG201000998-3A patent/SG159550A1/en unknown
- 2006-02-13 CN CN2006800047251A patent/CN101119706B/zh not_active Expired - Fee Related
- 2006-02-13 WO PCT/EP2006/001287 patent/WO2006089656A2/en not_active Ceased
- 2006-02-13 MX MX2007010396A patent/MX2007010396A/es active IP Right Grant
- 2006-02-13 AU AU2006218177A patent/AU2006218177B2/en not_active Ceased
- 2006-02-17 PE PE2006000199A patent/PE20061011A1/es not_active Application Discontinuation
- 2006-02-23 AR AR20060100670A patent/AR054230A1/es not_active Application Discontinuation
- 2006-02-24 US US11/361,562 patent/US8877164B2/en not_active Expired - Fee Related
-
2007
- 2007-07-05 IL IL184449A patent/IL184449A0/en unknown
- 2007-07-24 TN TNP2007000289A patent/TNSN07289A1/en unknown
- 2007-08-16 ZA ZA200706870A patent/ZA200706870B/xx unknown
- 2007-09-11 MA MA30220A patent/MA29333B1/fr unknown
- 2007-09-24 NO NO20074854A patent/NO20074854L/no not_active Application Discontinuation
-
2015
- 2015-04-06 AR ARP150101030A patent/AR099963A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008537729A (ja) | 2008-09-25 |
| KR20070107002A (ko) | 2007-11-06 |
| CA2594127A1 (en) | 2006-08-31 |
| BRPI0607990A2 (pt) | 2009-10-27 |
| GEP20105040B (en) | 2010-07-12 |
| HK1116337A1 (en) | 2008-12-19 |
| EA200701805A1 (ru) | 2008-02-28 |
| MX2007010396A (es) | 2007-10-19 |
| TNSN07289A1 (en) | 2008-12-31 |
| ZA200706870B (en) | 2008-11-26 |
| EP1850831B1 (en) | 2015-12-02 |
| AU2006218177B2 (en) | 2012-04-12 |
| EP1850831A2 (en) | 2007-11-07 |
| US20060193785A1 (en) | 2006-08-31 |
| MA29333B1 (fr) | 2008-03-03 |
| SG159550A1 (en) | 2010-03-30 |
| CN101119706A (zh) | 2008-02-06 |
| UA92732C2 (ru) | 2010-12-10 |
| WO2006089656A3 (en) | 2006-12-21 |
| NZ556376A (en) | 2010-01-29 |
| IL184449A0 (en) | 2007-10-31 |
| CN101119706B (zh) | 2013-04-17 |
| AR054230A1 (es) | 2007-06-13 |
| NO20074854L (no) | 2007-09-24 |
| JP5259193B2 (ja) | 2013-08-07 |
| PE20061011A1 (es) | 2006-12-08 |
| EA013405B1 (ru) | 2010-04-30 |
| WO2006089656A2 (en) | 2006-08-31 |
| AU2006218177A1 (en) | 2006-08-31 |
| KR101313959B1 (ko) | 2013-10-02 |
| CA2594127C (en) | 2013-10-15 |
| US8877164B2 (en) | 2014-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR099963A2 (es) | Formulación farmaceutica en aerosol para inhaladores de dosis medida presurizados que comprenden un agente secuestrante, inhalador y método para llenar | |
| PE20011323A1 (es) | Formulaciones farmaceuticas en solucion estable para inhaladores presurizados con medicion de dosis | |
| US3155574A (en) | Aerosol composition | |
| MX2021009476A (es) | Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano. | |
| CL2012001705A1 (es) | Composición farmacéutica que comprende a) bromuro de glicopirronio, b) formoterol o fumarato de formoterol y c) dipropionato de beclometasona, disueltos en hfa134a y etanol (entre 10-15 % p/p), hcl 1m entre 0,15-0,28µg/µl; frasco; combinación farmaceútica; método para rellenar el frasco; y su uso en asma y/o epoc | |
| CO5611092A2 (es) | Formulacion superfina de formoterol | |
| PE20240807A1 (es) | Composiciones, metodos y sistemas para la administracion de farmacos en aerosol | |
| ME02342B (me) | Farmaceutske formulacije rastvora za izmjerene doze inhalatora pod pritiskom | |
| PT656207E (pt) | Formulacoes de aerossois sem clorofluorocarbonetos | |
| PE20070951A1 (es) | Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva | |
| PE20011271A1 (es) | Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares | |
| AR057180A1 (es) | Formulacion farmaceutica de absorcion oral que comprende insulina, entre otros, y su metodo de administracion | |
| NZ600789A (en) | Aerosol formulation for copd | |
| ECSP088732A (es) | Aerosoles dosificadores para la administración de preparaciones farmacéuticas | |
| PE20221867A1 (es) | Inhaladores de dosis medida presurizada que comprenden una formulacion farmaceutica amortiguada | |
| CL2023000998A1 (es) | Formulación farmacéutica para inhalador presurizado de dosis medidas | |
| ES2568913T3 (es) | Formulaciones farmacéuticas en aerosol de formoterol y dipropionato de beclometasona | |
| AR041873A1 (es) | Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante | |
| AR057745A1 (es) | Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol | |
| ES2259915B1 (es) | Nueva formulacion estable de aerosoles en suspension y procedimiento de obtencion. | |
| ES2270166T3 (es) | Aerosoles dosificados con lecitina como sustancia tensioactiva. | |
| ES2230066T3 (es) | Aerosoles dosificadores con isobutano como propelente. | |
| CL2024003597A1 (es) | Formulación farmacéutica para inhalador presurizado de dosis medidas. | |
| JP5409594B2 (ja) | 加圧式定量吸入器のための安定な製薬学的溶液製剤 | |
| AR085443A1 (es) | Formulaciones medicinales en aerosol que no dañan la capa de ozono y con bajo efecto invernadero |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |